OSLO, Norway, May 31, 2019 /PRNewswire/ -- Three of the board
members of Nordic Nanovector ASA (the "Company"), Gisela Schwab, Joanna
Horobin and Jean-Pierre
Bizzari, have resolved to settle a total number of 11,840
RSUs that were issued to them in June
2018 after they had elected to receive all or part of their
remuneration for the period from the annual general meeting in 2018
to the annual general meeting in 2019 in RSUs. In addition, a
former board member has resolved to settle a total number of 7,000
RSUs that the Company has previously issued as remuneration under
the RSU-program. Each RSU gives the right to subscribe for one
share in the Company at a subscription price of NOK 0.20.
The Board of Directors of the Company has, to fulfil the
Company's obligations under the RSU agreements, resolved to issue
18,840 new shares at a subscription price of NOK 0.20 per share giving a total subscription
amount of NOK 3,768. The shares are
issued pursuant to the authorisation granted to the Board of
Directors at the annual general meeting held on 25 April 2019. Subsequent to the issuance of the
new shares, the Company's share capital will be NOK 10,941,288.60 divided into 54,706,443 shares,
each with a nominal value of NOK
0.20.
Gisela Schwab, Joanna Horobin and Jean-Pierre Bizzari have subscribed for 5,732
new shares, 4,072 new shares and 2,036 new shares respectively. The
three board members will following issuance of the new shares, have
the following holding of shares and RSUs in the Company:
Name
|
Total number of
RSUs
|
Total number of
shares
|
Gisela
Schwab
|
2,331
|
15,732
|
Joanna
Horobin
|
4,953
|
8,857
|
Jean-Pierre
Bizzari
|
2,477
|
6,545
|
For further information, please contact:
Malene Brondberg, VP Investor Relations and Corporate
Communications
Cell: +44-7561-431-762
Email: ir@nordicnanovector.com
About Nordic Nanovector
Nordic Nanovector is committed to develop and deliver innovative
therapies to patients to address major unmet medical needs and
advance cancer care. The Company aspires to become a leader in the
development of targeted therapies for haematological cancers.
Nordic Nanovector's lead clinical-stage candidate is Betalutin®,
a novel CD37 -targeting radioimmunotherapy designed to advance the
treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication
with substantial unmet medical need, representing a growing market
forecast to be worth nearly USD 29
billion by 2026. Nordic Nanovector intends to retain
marketing rights and to actively participate in the
commercialisation of Betalutin® in core markets. Further
information can be found at www.nordicnanovector.com.
This information is subject to a duty of disclosure pursuant to
section 3.2 of the continuing obligations for listed companies.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa--increase-of-share-capital,c2829163
View original
content:http://www.prnewswire.com/news-releases/nordic-nanovector-asa-increase-of-share-capital-300859695.html
SOURCE Nordic Nanovector